D
Beam Therapeutics Inc.
BEAM
$15.22
-$1.24-7.53%
D
Sell
12/2/2024Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 12/2/2024 due to an increase in the volatility index and total return index.
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 12/2/2024 due to an increase in the volatility index and total return index.
E
Sell
10/28/2024Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 10/28/2024 due to a decline in the volatility index.
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 10/28/2024 due to a decline in the volatility index.
D
Sell
10/11/2024Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 10/11/2024 due to an increase in the total return index and valuation index.
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 10/11/2024 due to an increase in the total return index and valuation index.
E
Sell
9/26/2024Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 9/26/2024 due to a decline in the volatility index.
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 9/26/2024 due to a decline in the volatility index.
D
Sell
8/15/2024Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 8/15/2024 due to a significant increase in the growth index, total return index and valuation index. Total revenue increased 58.87% from $7.41M to $11.77M, operating cash flow increased 16.78% from -$99.75M to -$83.01M, and earnings per share increased from -$1.2077 to -$1.1062.
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 8/15/2024 due to a significant increase in the growth index, total return index and valuation index. Total revenue increased 58.87% from $7.41M to $11.77M, operating cash flow increased 16.78% from -$99.75M to -$83.01M, and earnings per share increased from -$1.2077 to -$1.1062.
E
Sell
8/6/2024Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 8/6/2024 due to a decline in the valuation index.
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 8/6/2024 due to a decline in the valuation index.
D
Sell
7/22/2024Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 7/22/2024 due to an increase in the volatility index.
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 7/22/2024 due to an increase in the volatility index.
E
Sell
6/10/2024Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 6/10/2024 due to a noticeable decline in the growth index and valuation index. EBIT declined 178.38% from $132.86M to -$104.13M, operating cash flow declined 173.85% from $135.07M to -$99.75M, and earnings per share declined from $1.7266 to -$1.2077.
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 6/10/2024 due to a noticeable decline in the growth index and valuation index. EBIT declined 178.38% from $132.86M to -$104.13M, operating cash flow declined 173.85% from $135.07M to -$99.75M, and earnings per share declined from $1.7266 to -$1.2077.
D
Sell
12/26/2023Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index.
Beam Therapeutics Inc. (BEAM) was upgraded to D- from E+ on 12/26/2023 due to an increase in the volatility index.
E
Sell
10/5/2023Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 10/5/2023 due to a decline in the volatility index and total return index.
Beam Therapeutics Inc. (BEAM) was downgraded to E+ from D- on 10/5/2023 due to a decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index.
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the growth index and solvency index.
D
Sell
2/23/2023Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index and volatility index.
Beam Therapeutics Inc. (BEAM) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index and volatility index.
D
Sell
2/8/2023Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index, total return index and valuation index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 5.49 to 4.58.
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index, total return index and valuation index. Debt to equity increased from 0.01 to 0.02, and the quick ratio declined from 5.49 to 4.58.
D
Sell
6/13/2022Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to D from D+ on 6/13/2022 due to a decline in the volatility index.
Beam Therapeutics Inc. (BEAM) was downgraded to D from D+ on 6/13/2022 due to a decline in the volatility index.
D
Sell
5/16/2022Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D+ from D- on 05/16/2022.
Beam Therapeutics Inc. (BEAM) was upgraded to D+ from D- on 05/16/2022.
D
Sell
5/13/2022Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D+ on 5/13/2022 due to a decline in the volatility index and total return index.
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D+ on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/10/2022Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D+ from D on 5/10/2022 due to a noticeable increase in the growth index. Operating cash flow increased 11,839.34% from $1.83M to $218.49M.
Beam Therapeutics Inc. (BEAM) was upgraded to D+ from D on 5/10/2022 due to a noticeable increase in the growth index. Operating cash flow increased 11,839.34% from $1.83M to $218.49M.
D
Sell
5/5/2022Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
Beam Therapeutics Inc. (BEAM) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.4236 to -$0.9517, the quick ratio declined from 9.21 to 4.52, and operating cash flow declined 39.14% from $3.01M to $1.83M.
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 4/20/2022 due to a noticeable decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.4236 to -$0.9517, the quick ratio declined from 9.21 to 4.52, and operating cash flow declined 39.14% from $3.01M to $1.83M.
D
Sell
11/11/2021Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D from D- on 11/11/2021 due to an increase in the valuation index and total return index.
Beam Therapeutics Inc. (BEAM) was upgraded to D from D- on 11/11/2021 due to an increase in the valuation index and total return index.
D
Sell
11/8/2021Downgrade
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 11/8/2021 due to a large decline in the efficiency index and valuation index.
Beam Therapeutics Inc. (BEAM) was downgraded to D- from D on 11/8/2021 due to a large decline in the efficiency index and valuation index.
D
Sell
7/15/2020Upgraded
Beam Therapeutics Inc. (BEAM) was upgraded to D from E- on 7/15/2020 due to a significant increase in the solvency index, efficiency index and total return index. The quick ratio increased from 3.15 to 8.06, and total capital increased 124.8% from $132.18M to $297.15M.
Beam Therapeutics Inc. (BEAM) was upgraded to D from E- on 7/15/2020 due to a significant increase in the solvency index, efficiency index and total return index. The quick ratio increased from 3.15 to 8.06, and total capital increased 124.8% from $132.18M to $297.15M.
E
Sell
5/1/2020None
Beam Therapeutics Inc. (BEAM) was downgraded to E- from U on 05/01/2020.
Beam Therapeutics Inc. (BEAM) was downgraded to E- from U on 05/01/2020.
NASDAQ
04/04/2025 12:58PM Eastern
Quotes delayed
